At present, the most widely accepted solution for addressing short stature is the injection of recombinant human growth hormone (hGH). However, due to the systemic effects of hGH, some patients with potential risks for complications cannot opt for hGH injections. A breakthrough solution that balances applicability and efficacy is urgently needed worldwide. Furthermore, most patients are required to self-administer injections, which can be daunting. Consequently, the market has long anticipated a more convenient oral formulation.

Insulin-like growth factor-1 (IGF-1) is a bioactive polypeptide substance primarily secreted by the liver. The hGH secreted by the pituitary gland binds with hGHR in the liver, leading to the secretion of IGF-1. IGF-1 then binds with IGF-1 receptors in bone and skeletal muscle cells, promoting bone cell division and proliferation, ultimately facilitating height growth. As such, hGH and IGF-1 are the two critical components of height growth mechanisms, making them powerful targets for treating short stature.

Driven by the mission to "extend human healthspan, improve quality of life, and expand life expectancy," five co-founders from Zhejiang University established Xregen in 2021, aiming to provide quantifiable health solutions using cutting-edge biomedicine technologies. The company's technical backbone comprises Ph.D. holders from prestigious universities worldwide, with backgrounds in biology. Meanwhile, Xregen's China Research Institute collaborates closely with its US laboratory and top-tier universities both domestically and internationally to conduct more frontier research.

Xregen's iKids-Growth supplement, an oral solution for short stature, is designed to increase receptor sensitivity and enhance the efficiency of the entire growth pathway. Its more convenient and easier administration signifies a new step forward in global height-boosting solutions.